DOCSLIB.ORG

Photosensitizing Medications List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Photosensitizing Medications List M E D I C Feeling sun-sensitive? A T medications, topical solutions, and even some foods, can cause the skin to burn or break out in Many a rash when exposed to ultraviolet light. The consequences can range from itchiness to an I uncomfortable rash and burns. O If you tan at an indoor tanning salon, there should be a chart posted of photosensitive medications and agents. N If you are taking a medication that isn’t listed, you should consult your physician or a pharmacist before being exposed to ultraviolet light—indoors or outdoors. The most common photosensitizing materials are listed on the following pages. This is not a list of every L material that could have photosensitizing effects. Before using the list, you should be aware of the following: I • NOT all individuals who use or take these medications will experience a photosensitive reaction. Also, an indi- vidual who experiences a photosensitive reaction on one occasion will NOT necessarily experience it again or S every time. T • A medication will NOT cause the same degree of skin reaction in all individuals. • Brand names of products should be considered only as examples; they do NOT represent all names under which the generic product may be sold. The following list was prepared by Jerome I. Levine, M.S., R.Ph., of the Food and Drug Administration. The list was published under the title “Medications That Increase Sensitivity To Light: A 1990 Listing.” The FDA has con- firmed this list to be the most recent. The mention of commercial products, their sources, or their use in connection with material reported herein is not to be construed as either an actual or implied endorsement of such products by the Department of Health and Human Services. Reported Photosensitizing Medications Generic Name Brand Name Therapeutic Class Generic Name Brand Name Therapeutic Class Doxycycline Vibramycin Antibiotic Acetazolamide Diamox Anticonvulsant, Antiglaucoma diuretic Doxycycline Hyclate Doryx Antibiotic Amiloride + Hydrochlorothizide Moduretic Antihypertensive, Thiazide diuretic Enalapril Vasotec Antihypertensive Amiodarone Cordarone (15%) Antiarrhythmic Enalapril + Hydrochlorothiazide Vaseretic Antihypertensive, Thiazide diuretic Amitriptyline Elavil Antidepressant (tricyclic) Erythromycin Ethylsuccinate + Sulfisoxazole Pediazole Antibiotic Amitriptyline Endep Antidepressant (tricyclic) Estrogens Contraceptive, oral Female sex hormone Amoxapine Asendin (<1%) Antidepressant (tricyclic) Estrogens Estrogens Female sex hormone Astemizole Hismanal Antihistamine Ethionamide Trecator-SC Anti-infective, Antituberculosis Atenolol + Chlorthalidone Tenoretic Beta-adrenergic blocker Thiazide diuretic Etretinate Tegison Antipsoriatic Auranofin Ridaura Antiarthritic, Gold compound Floxuridine FUDR Injectable Antimetabolite, Antineoplastic Azatadine Optimine Antihistamine Flucytosine Ancobon Antifungal Azatidine + Pseudoephedrine Trinalin Repetabs Antihistamine, Decongestant Fluorouracil Adrucil Antineoplastic Bendroflumethiazide Naturetin Antihypertensive, Thiazide diuretic Fluorouracil Efudex Antineoplastic Benzthiazide Exna Antihypertensive, Thiazide diuretic Fluorouracil Fluorouracil Antineoplastic Bromodiphenhydramine Ambenyl Antihistamine Fluphenazine Prolixin Antipsychotic, Tranquilizer Brompheniramine Dimetane Antihistamine Fluphenazine Permitil Antipsychotic, Tranquilizer Captopril Capoten Antihypertensive Flurbiprofen Ansaid NSAID,* antiarthritic Captopril + Hydrochlorothiazide Capozide Antihypertensive, Thiazide diuretic Flutamide Eulexin Antimetastatic (prostatic carcinoma) Carbamazepine Tegretol Analgesic, Anticonvulsant Furosemide Lasix Antihypertensive, Diuretic Chlordiazepoxide + Amitriptyline Limbitrol Antidepressant (tricyclic) Tranquilizer Gentamicin Garamycin Antibiotic Chlorothiazide Diuril Antihypertensive, Thiazide diuretic Glipizide Glucotrol Antidiabetic (oral),Sulfonylurea Chlorpheniramine Chlorpheniramine Antihistamine Glyburide Diabeta Antidiabetic (oral),Sulfonylurea Chlorpheniramin + D-Pseudoephedrine Deconamine Antihistamine, Decongestant Glyburide Micronase Antidiabetic (oral), Sulfonylurea Chlorpheniramine + Phenylpropanolamine Ru-Tuss II Antihistamine, Decongestant Gold Salts (compounds) Solganal Antiarthritic, Gold compound Chlorpromazine Thorazine Antiemetic, Tranquilizer Gold Sodium Thiomalate Myochrysine Antiarthritic, Gold compound Chlorpropamide Diabinese Antidiabetic (oral), Sulfonylurea Griseofulvin Fulvicin U/F Antibiotic, Antifungal Chlorprothixene Taractan Antiemetic, Tranquilizer Griseofulvin Ultramicrosize Grisactin Ultra Antibiotic, Antifungal Chlorthalidone Hygroton Antihypertensive, Thiazide diuretic Guanethidine + Hydrochlorothiazide Esimil Antihypertensive, Thiazide diuretic Chlorthalidone Thalitone Antihypertensive, Thiazide diuretic Haloperidol Haldol Antipsychotic, Tranquilizer Chlorthalidone + Reserpine Demi-Regroton Antihypertensive, Thiazide diuretic Hexachlorophene Phisohex Antibacterial Chlorthalidone + Reserpine Regroton Antihypertensive, Thiazide diuretic Hydralazine + Hydrochlorothiazide Apresazide Antihypertensive, Thiazide diuretic Ciprofloxacin Cipro (<1%) Anti-infective Hydralazine Apresoline-Esidrix Antihypertensive, Thiazide diuretic Clemastine Tavist Antihistamine Hydrochlorothiazide Esidrix Antihypertensive, Thiazide diuretic Clofazime Lamprene (<1%) Antibacterial, Antileprosy agent Hydrochlorothiazide Hydrodiuril Antihypertensive, Thiazide diuretic Clonidine Chlorthalidone + Combipres Antihypertensive, Thiazide diuretic Hydrochlorothiazide Oretic Antihypertensive, Thiazide diuretic Coal Tar Estar Gel Antipsoriatic, Eczema Hydrochlorothiazide Oreticyl Antihypertensive, Thiazide diuretic Coal Tar Balnetar Antipsoriatic, Eczema Hydrochlorothiazide + Triamterene Dyazide Antihypertensive, Thiazide diuretic Contraceptive, oral Estrogen Birth control pill, Female sex hormone Hydrochlorothiazide Maxzide Antihypertensive, Thiazide diuretic Cromolyn Intal Inhaler Antiasthmatic Hydroflumethiazide Diucardin Antihypertensive, Thiazide diuretic Cyclobenzaprine Flexeril Anti-skeletal, Muscle spasms Hydroflumethiazide Saluron Antihypertensive, Thiazide diuretic Cyproheptadine Periactin Antihistamine, Antiserotonergic Hydroflumethiazide + Reserpine Salutensin/ Dacarbazine DTIC-Dome Anti-Hodgkin’s disease, Antimetabolite Salutensin-Demi Antihypertensive, Thiazide diuretic Danazol Danocrine Gonadotropin inhibitor Ibuprofen Advil (<1%) NSAID,* antiarthritic Demeclocycline Declomycin Antibiotic Ibuprofen Motrin (<1%) NSAID,* antiarthritic Desipramine Norpramin Antidepressant (tricyclic) Imipramine Tofranil Antidepressant (tricyclic) Desipramine Pertofrane Antidepressant (tricyclic) Indapamide Lozol Antihypertensive, Diuretic Dexchlorpheniramine Polaramine Antihistamine Interferon ALFA-2B Intron A (<1%) Antiviral agent Diclofenac Voltaren (<1%) NSAID,* antiarthritic Isocarboxazid Marplan Antidepressant, MAO inhibitor Diflunisal Dolobid (<1%) NSAID,* antiarthritic Isotretinoin Accutane Antiacne Diltiazem Cardizem (<1%) Antianginal, Antihypertensive, Calcium Ketoprofen Orudis (<1%) NSAID,* antiarthritic channel blocker Labetalol Normodyne Antihypertensive,Beta- and Diphenhydramine Benadryl Antihistamine alpha-adrenergic blocker Diphenylpyraline Hispril Spansule Antihistamine Labetalol + Hydrochlorothiazide Normozide Beta- and alpha-adrenergic Doxepin Sinequan Antidepressant (tricyclic) blocker, Thiazide diuretic Doxycycline Vibramycin Antibiotic Doxycycline Hyclate Doryx Antibiotic 36 SUNWELLNESS April/May 2000 Generic Name Brand Name Therapeutic Class Photosensitizing Foods And Medications “ ” Trandate HCT Beta- and alpha-adrenergic blocker, Researchers, including Dr. Richard Childers, a dermatologist at the University of Florida, and Dr. Edward Emmett, of Thiazide diuretic Johns Hopkins University, compiled this list of drugs, foods and other substances which could make your skin super Lisinopril + Hydrochlorothiazide Prinzide Antihypertensive, Thiazide diuretic sensitive to ultraviolet light. Should you be taking any of the following, a doctor’s release is necessary before you “ ” Zestoretic Antihypertensive, Thiazide diuretic begin tanning with an indoor tanning system. After the doctor’s release is complete and you have begun the tanning Lovastatin Mevacor Anticholesterol process, should there be any negative reactions experienced, PLEASE notify the receptionist immediately. Maprotiline Ludiomil Antidepressant Meperidine + Promethiazine Mepergan Narcotic analgesic Acridine Preparations (slight) Glyceryl P-Aminobenzoate Profriptyline Mesoridazine Serentil Antipsychotic, Tranquilizer Agave Lechuguilla (amarylis) Grass (meadow) Pyrathiazine Hydrochloride Methacycline Rondomycin Antibiotic Agrimony Hematoporphyrin Pyridine Methazolamide Neptazane Antiglaucoma 9-Aminoacridine Hexachlorophene (rare) Rose Bengal perfume Methdilazine Tacaryl Antihistamine, Antipruritic Aminobenzoic Acid Imipramine HCI (Tofranil) Rue Methotrexate Folex Antimetabolite, Antipsoriatic Anesthetica (procaine group) Isothipencyl (Theruhistin) Salicylanilides “ ” Methotrexate Antimetabolite, Antipsoriatic Angelica Isothipendyl Salicylates “ ” Mexate & Mexate-AQ Antimetabolite, Antipsoriatic Anthracene Lady’s Thumb (tea) Silver Salts Methyclothiazide Aquatensen Antihypertensive, Thiazide diuretic Antimalarials Lantinin Smartweed (tea) “ ” Enduron Antihypertensive, Thiazide diuretic Aresenicals Meclothiazide (Enduron) Stilbamindine Isethionate Methyclothiazide + Deserpidine Enduronyl Antihypertensive, Thiazide diuretic Barbiturates Mepazine (Pacatal) Sulfacetamide Methyclothiazide
Load more

Recommended publications
  • Alzheimer's Disease, a Decade of Treatment: What Have We Learned?
    A Critical Look at Medication Dementia: Alzheimer’s Disease Management Issues in Alzheimer’s Disease R.Ron Finley, B.S. Pharm., R.Ph,CGP Lecturer (Emeritus) and Assistant Clinical Professor, UCSF School of Pharmacy Clinical Pharmacist, UCSF Memory and Aging Center- Alzheimer’s Research Center Educational Objectives Disclosures 1. Define the role for cholinesterase inhibitors in the management of Alzheimer’s disease, Lewy Body dementia, Frontal Temporal Lobe dementia. Pfizer Speakers Bureau 2. Name three common side effects of atypical antipsychotic Forest Speakers Bureau drugs. Novartis Speakers Bureau 3. Construct a pharmacological treatment plan for a 77-year-old Rx Consultant Associate Editor patient diagnosed with Alzheimer’s disease and hallucinations. WindChime Consultant 4. Describe the role for antipsychotic, antidepressant, mood HGA HealthCare Consultant stabilizers and benzodiazepines in the management of psychiatric behavior problems related to Alzheimer’s disease. Elder Care Specialist Consultant 5. Cite three potential drug or disease interactions with cholinesterase inhibitors. The Many Faces of Dementia Risk Factors Linked to AD Alzheimer’s Disease Over 65 years of age and increases Vascular: Multi-infarct with age FrontalTemporal Lobe dementia ( FTD) and female Pick’s disease Head injury Lewy Body Dementia Progressive Supranuclear Palsy Factors associated with DM, HTN, CVD Corticobasal Degeneration Genetic: family history, specific Primary Progressive Aphasia chromosome mutations Huntington’s disease
    [Show full text]
  • Synthetic Drugs
    Comprehensive and Confident Identification of Narcotics, Steroids and Pharmaceuticals in Urine David E. Alonso1, Petra Gerhards2, Charles Lyle1 and Joe Binkley1 | 1LECO Corporation, St. Joseph, MI; 2LECO European LSCA Centre, Moenchengladbach, Germany Introduction Experimental Sample A (Traditional Drugs) Sample B (Synthetic Drugs) Monitoring of patients in hospitals and clinics has traditionally relied on Samples Representative Compounds Representative Compounds targeted methods of analysis. These screening methods are not Peak # Name Formula R.T. (s) Area Similarity Mass Delta (mDa) MA (ppm) 1 Creatinine ME C5H9N3O 210 1326229 800 -0.05 -0.43 • Obtained from a collaborating European hospital 3.5e6 3.0e6 Peak # Name Formula R.T. (s) Area Similarity 2 o-Ethynylaniline C8H7N 219 167436 893 0.07 0.63 1 Indole C8H7N 213 2744171 917 comprehensive and result in an incomplete picture of a patient’s 3 2-Methoxy-4-vinylphenol C H O 223 65764 805 0.11 0.73 52 patient monitoring samples 9 10 2 2 Creatinine ME C5H9N3O 216 613318 651 • 2.5e6 4 Nicotine C10H14N2 234 3249121 898 -0.21 -1.29 3 Pyridine, 2-(1-methyl-2-pyrrolidinyl)- C10H14N2 230 24869771 899 activities. Gas chromatography high resolution time-of-flight mass 3.0e6 5 Hordenin C10H15NO 274 949734 775 -0.14 -0.84 4 Parabanic acid, 1-methyl- C4H4N2O3 233 434278 764 Sample preparation 5 Cotinine C10H12N2O 336 27810908 918 • 6 Methylecgonine C10H17NO3 276 104640 835 -0.22 -1.1 spectrometry (GC-HRT) provides a fast and convenient method for 2.0e6 5 6 Caffeine C8H10N4O2 371 3753598 797 2.5e6 7 4-(3-Pyridyl-tetrahydrofuran-2-one C9H9NO2 313 93817 849 -0.11 -0.68 3,4 7 1-methyl-7H-xanthine C6H6N4O2 437 4868196 850 analysis of urine samples.
    [Show full text]
  • PEMD-91-12BR Off-Label Drugs: Initial Results of a National Survey
    11 1; -- __...._-----. ^.-- ______ -..._._ _.__ - _........ - t Ji Jo United States General Accounting Office Washington, D.C. 20648 Program Evaluation and Methodology Division B-242851 February 25,199l The Honorable Edward M. Kennedy Chairman, Committee on Labor and Human Resources United States Senate Dear Mr. Chairman: In September 1989, you asked us to conduct a study on reimbursement denials by health insurers for off-label drug use. As you know, the Food and Drug Administration designates the specific clinical indications for which a drug has been proven effective on a label insert for each approved drug, “Off-label” drug use occurs when physicians prescribe a drug for clinical indications other than those listed on the label. In response to your request, we surveyed a nationally representative sample of oncologists to determine: . the prevalence of off-label use of anticancer drugs by oncologists and how use varies by clinical, demographic, and geographic factors; l the extent to which third-party payers (for example, Medicare intermediaries, private health insurers) are denying payment for such use; and l whether the policies of third-party payers are influencing the treatment of cancer patients. We randomly selected 1,470 members of the American Society of Clinical Oncologists and sent them our survey in March 1990. The sam- pling was structured to ensure that our results would be generalizable both to the nation and to the 11 states with the largest number of oncologists. Our response rate was 56 percent, and a comparison of respondents to nonrespondents shows no noteworthy differences between the two groups.
    [Show full text]
  • Intranasal Rhinitis Agents
    Intranasal Rhinitis Agents Therapeutic Class Review (TCR) February 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected].
    [Show full text]
  • MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted
    MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List The agents listed below are the antihistamine/decongestant drug products listed in the Mississippi Medicaid Preferred Drug List (PDL). This is a cross-reference between the drug product name and its active ingredients to reference the antihistamine/decongestant portion of the PDL. For more information concerning the PDL, including non- preferred agents, the OTC formulary, and other specifics, please visit our website at www.medicaid.ms.gov. List Effective 07/16/10 Therapeutic Class Active Ingredients Preferred Non-Preferred ANTIHISTAMINES - 1ST GENERATION BROMPHENIRAMINE MALEATE BPM BROMAX BROMPHENIRAMINE MALEATE J-TAN PD BROMSPIRO LODRANE 24 LOHIST 12HR VAZOL BROMPHENIRAMINE TANNATE BROMPHENIRAMINE TANNATE J-TAN P-TEX BROMPHENIRAMINE/DIPHENHYDRAM ALA-HIST CARBINOXAMINE MALEATE CARBINOXAMINE MALEATE PALGIC CHLORPHENIRAMINE MALEATE CHLORPHENIRAMINE MALEATE CPM 12 CHLORPHENIRAMINE TANNATE ED CHLORPED ED-CHLOR-TAN MYCI CHLOR-TAN MYCI CHLORPED PEDIAPHYL TANAHIST-PD CLEMASTINE FUMARATE CLEMASTINE FUMARATE CYPROHEPTADINE HCL CYPROHEPTADINE HCL DEXCHLORPHENIRAMINE MALEATE DEXCHLORPHENIRAMINE MALEATE DIPHENHYDRAMINE HCL ALLERGY MEDICINE ALLERGY RELIEF BANOPHEN BENADRYL BENADRYL ALLERGY CHILDREN'S ALLERGY CHILDREN'S COLD & ALLERGY COMPLETE ALLERGY DIPHEDRYL DIPHENDRYL DIPHENHIST DIPHENHYDRAMINE HCL DYTUSS GENAHIST HYDRAMINE MEDI-PHEDRYL PHARBEDRYL Q-DRYL QUENALIN SILADRYL SILPHEN DIPHENHYDRAMINE TANNATE DIPHENMAX DOXYLAMINE SUCCINATE
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Drug Class Review Antianginal Agents
    Drug Class Review Antianginal Agents 24:12.08 Nitrates and Nitrites 24:04.92 Cardiac Drugs, Miscellaneous Amyl Nitrite Isosorbide Dinitrate (IsoDitrate ER®, others) Isosorbide Mononitrate (Imdur®) Nitroglycerin (Minitran®, Nitrostat®, others) Ranolazine (Ranexa®) Final Report May 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Antianginal Therapies .............................................................................................. 4 Table 2. Summary of Agents .................................................................................................. 5 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Clinical Practice Guidelines .................................................... 9 Pharmacology ............................................................................................................................... 10 Table 4. Pharmacokinetic Properties
    [Show full text]
  • 2-Bromopyridine Safety Data Sheet Jubilant Ingrevia Limited
    2-Bromopyridine Safety Data Sheet According to the federal final rule of hazard communication revised on 2012 (HazCom 2012) Date of Compilation : July 03 ’ 2019 Date of Revision : February 09 ’ 2021 Revision due date : January 2024 Revision Number : 01 Version Name : 0034Gj Ghs01 Div.3 sds 2-Bromopyridine Supersedes date : July 03 ’ 2019 Supersedes version : 0034Gj Ghs00 Div.3 sds 2-Bromopyridine Jubilant Ingrevia Limited Page 1 of 9 2-Bromopyridine Safety Data Sheet According to the federal final rule of hazard communication revised on 2012 (HazCom 2012) SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1. Product identifier PRODUCT NAME : 2-Bromopyridine CAS RN : 109-04-6 EC# : 203-641-6 SYNONYMS : 2-Pyridyl bromide, Pyridine, 2-bromo-, beta-Bromopyridine, o-Bromopyridine SYSTEMATIC NAME : 2-Bromopyridine, -Pyridine, 2-bromo- MOLECULAR FORMULA : C5H4BrN STRUCTURAL FORMULA N Br 1.2. Relevant identified uses of the substance or mixture and uses advised against 1.2.1. Relevant identified uses 2-Bromopyridine is used as an intermediate in the pharmaceutical industry for the manufacture of Atazanavir (an antiretroviral drug), Carbinoxamine, Chloropyramine, triprolidine (antihistamine drugs), Disopyramide Phosphate (an antiarrythmic drug), Mefloquine (antimalarial drug), Pipradrol (mild CNS stimulant) etc. Uses advised against: None 1.3. Details of the supplier of the safety data sheet Jubilant Ingrevia Limited REGISTERED & FACTORY OFFICE: Jubilant Ingrevia Limited Bhartiagram, Gajraula , District: Amroha, Uttar Pradesh-244223, India PHONE NO: +91-5924-252353 to 252360 Contact Department-Safety: Ext. 7424 , FAX NO : +91-5924-252352 HEAD OFFICE: Jubilant Ingrevia Limited, Plot 1-A, Sector 16-A,Institutional Area, Noida, Uttar Pradesh, 201301 - India T +91-120-4361000 - F +91-120-4234881 / 84 / 85 / 87 / 95 / 96 [email protected] -www.jubilantingrevia.com 1.4.
    [Show full text]
  • Download Article (PDF)
    Use of astemizole in a large group practice TIMOTHY J. CRAIG, DO MARK GREENWALD, MD VANESSA KAUFFMANN JILL CRAIG, MS Astemizole was released in 1988. Shortly after the release of astemizole and terfe­ In late 1992, a new warning label was added nadine, it became evident that both were associat­ in response to reports of syncope and death ed with prolonged QT intervals and arrhythmias, from arrhythmia. Records of patients given new mainly torsades de pointes. Because of this associ­ prescriptions for astemizole were reviewed ation, the Food and Drug Administration (FDA) and to assess compliance with the warnings in a the manufacturers provided a warning letter to large multispecialty practice. The indication physicians in 1992.1 For astemizole, the warning was appropriate in 89% of cases. Excessive stated: (1) That arrhythmias have usually occurred doses were used in 4% of cases. Two percent when the dose of 10 mg/d (the recommended dose) of prescriptions were given to patients with was exceeded. Exceeding this dose and the use of contraindications. Only two complications loading doses should be avoided. (2) Serum levels were documented. Despite carrying a drug of astemizole may be elevated by ketoconazole, ery­ warning, astemizole continues to be used thromycin;, and itraconazole. These drugs should inappropriately and is a medicolegal concern. not be used together. (3) Presyncope and syncope Education and drug evaluations can be used may precede fatal arrhythmias and calls for dis­ to enhance compliance and decrease the risk continuing astemizole. (4) The drug should be avoid­ associated with the use of astemizole. ed in patients with significant liver disease.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Treatment of Schizophrenia Course Director: Philip Janicak, M.D
    S6735- Treatment of Schizophrenia Course Director: Philip Janicak, M.D. #APAAM2016 Saturday, May 14, 2016 Marriott Marquis - Marquis Ballroom D psychiatry.org/ annualmeetingS4637 ANNUAL MEETING May 14-18, 2016 • Atlanta Reference • Janicak PG, Marder SR, Tandon R, Goldman M (Eds.). Schizophrenia: Recent Advances in Diagnosis and Treatment. New York, NY: Springer; 2014. Schizophrenia: Recent Diagnostic Advances, Neurobiology, and the Neuropharmacology of Antipsychotic Drug Therapy Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine Gainesville, Florida Annual Meeting of the American Psychiatric Association New York, New York May 3–7, 2014 Disclosure Information MEMBER, WPA PHARMACOPSYCHIATRY SECTION MEMBER, DSM-5 WORKGROUP ON PSYCHOTIC DISORDERS A CLINICIAN AND CLINICAL RESEARCHER Pharmacological Treatment of Any Disease • Know the Disease that you are treating • Nature; Treatment targets; Treatment goals; • Know the Treatments at your disposal • What they do; How they compare; Costs; • Principles of Treatment • Measurement-based; Targeted; Individualized Program Outline • Nature and Definition of psychosis? • Clinical description • What is wrong in psychotic illness • Dimensions of Psychopathology • Neurobiological Abnormalities • Mechanisms underlying antipsychotic effects? • What contributes to Efficacy • Basis of Side-effect differences 5 Challenges in DSM-IV Construct of Psychotic Disorders ♦ Indistinct Boundaries ♦ With Other Disorders (eg., with OCD) ♦ Within Group of Psychotic Disorders (eg. between
    [Show full text]